Suitable for use to measure free Nivolumab in patient samples.
Recommended antibody pair for pharmacokinetic (PK) bridging assay to measure free drug: CABT-ZB212 - CABT-ZB213; CABT-ZB212 - CABT-ZB214
Recommended Working Concentration: 0.01-0.1 μg/ml
Summary
Specifications
Antibody Isotype
IgG1
Clone
9H7H4E9
Immunogen
Nivolumab
Conjugate
Unconjugated
Applications
Application Notes
Suitable for use in PK bridging ELISA. We recommend the following for sandwich ELISA (Capture - Detection): CABT-ZB212 - CABT-ZB213; CABT-ZB212 - CABT-ZB214 Recommended Working Concentration: 0.01-0.1 μg/ml
General Notes
We recommend the following antibody pair to develop a pharmacokinetic (PK) bridging assay to measure free drug: CABT-ZB212 - CABT-ZB213; CABT-ZB212 - CABT-ZB214 CABT-ZB212 is recommended for use as a capture antibody when paired with CABT-ZB213 or CABT-ZB214 as a detection antibody. Nivolumab (Opdivo) is a humanized monoclonal antibody that is approved by the U.S. Food and Drug Administration for the treatment of patients with unresectable or metastatic melanoma. Nivolumab binds to the human cell surface receptor PD-1 (Programmed Cell Death Protein 1) and blocks its interaction with PD-L1, resulting in the activation of T-cell-mediated immune responses against tumor cells.
Target
Alternative Names
Mouse monoclonal antibody to Opdivo; MDX-1106; Nivolumab
Citations
Publication ()
Have you cited CABT-ZB212 in a publication? Let us know and earn a reward for your research.
My Review for Mouse Anti-Nivolumab monoclonal antibody, clone 9H7H4E9
Creative Diagnostics products are for RESEARCH USE ONLY, please make sure your review is research based.
Required fields are marked with *
Terms and conditions:
We will select high-quality review customers and offer a $30 coupon for your next purchase.
All product reviews must be submitted in the English language.
Creative Diagnostics will not share any personal information of applicants, and all information will be treated with strict confidentiality and will not be sold or disclosed to a third party.
COA
Publication 
Loading ......
